Richard Stanton has joined Lyndra Therapeutics as chief medical officer, the same role he held most recently at Pacira Pharmaceuticals. Lyndra is developing drug delivery technology that turns daily medications into extended-release formulations via a mechanism that keeps a drug in the stomach longer. Last year, the Watertown, MA-based company raised $55 million in Series B funding for clinical trials, manufacturing, and the expansion of its technology to more drugs.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
